Despite conflicting data regarding the pharmacological management of Borderline Personality Disorder (BPD), a recent ...
The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.
Hosted on MSN10d
Eli Lilly: 4 Reasons Investors Shouldn't Miss This OpportunityBacking out revenue for its olanzapine portfolio Zyprexa ... a triple agonist targeting GIP, GLP-1, and Glucagon receptors.
TEV’749 is a long-acting formulation of olanzapine, one of the most widely used atypical antipsychotic schizophrenia treatments to date. The drug was first approved in the 1990s and is currently ...
Research Center for Environmental Quality Management, Graduate School of Engineering, Kyoto University, Otsu, Shiga 520-0811, Japan Key Laboratory of Industrial Ecology and Environmental Engineering ...
Established guidelines for the management of chemotherapy-induced nausea and vomiting (CINV) currently recommend three main classes of drugs: 5-HT 3 receptor antagonists, NK 1 receptor antagonists ...
Dopamine receptors are a primary target of the SGAs, and many studies have tested whether variation in the dopamine receptor genes correlate with treatment response and/or side effect profiles.
The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State Key Laboratory of Physical Chemistry of Solid Surfaces, Department of Chemistry, College of Chemistry and Chemical ...
Currently, five atypical antipsychotics—aripiprazole, quetiapine XR, olanzapine, brexpiprazole ... through its agonism of 5-HT1A and 5-HT2A receptors and partial agonism of D2/D3 receptors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback